Glaxosmithkline Share News (GSK)

GlaxoSmithKline Reiterates 2015 Guidance As Third Quarter Profit Rises

HIV drugs and flu vaccines help GlaxoSmithKline beat forecasts

LONDON, Oct 28 (Reuters) - GlaxoSmithKline reported better-than-expected quarterly earnings on Wednesday, helped by strong demand for HIV drugs and flu vaccines, which offset a continued slide in sales of respiratory medicine. Sales, in sterling terms, rose 9 percent to 6.13 billion pounds

GlaxoSmithKline's consumer strength lifts third-quarter results above forecast

(ShareCast News) - GlaxoSmithKline posted third-quarter results with revenue and core earnings per share beating market expectations, though management held full year guidance steady. Revenues rose 11% to £6.13bn to beat consensus forecasts of £6.07bn and core EPS declines 13% at constant exchange r

Oxford Biomedica Says Glaxo Exercises LentiVector Platform Option

Wednesday preview: Federal Reserve announces interest rate decision

(ShareCast News) - The Federal Reserve is expected to stay put on interest rates when it makes its policy announcement on Wednesday. Economists predict the central bank will keep rates at 0.25% amid low inflation and concerns about the risks arising from a slowdown in emerging markets. "While expec

UPDATE 3-Novartis hit by $390 mln settlement in U.S. kickbacks case

* Q3 core net income down 2 pct to $3.06 bln vs f'cast $3.13 * Sales down 6 pct to $12.27 bln vs f'cast $12.62 bln * Alcon continues slump, recovery plan to be unveiled in Jan * Shares down 1.8 percent (Adds quotes from CEO, additional information on lawsuits) By John Mi

UPDATE 1-GSK heart drug flops in study, shingles vaccine on track

* Losmapimod fails to show efficacy in first part of study * Shingrix 90 pct effective in over-70s in latest trial (Adds detail on both products) By Ben Hirschler LONDON, Oct 27 (Reuters) - An experimental heart drug from GlaxoSmithKline failed to work as hoped in the first pa

UPDATE: Glaxo Gets Good Results On Asthma And Shingles Treatments

Glaxo gets good results from shingles and asthma treatments; heart drug disappoints

(ShareCast News) - GlaxoSmithKline has received positive results from studies on its asthma treatment, Advair Diskus and Shingrix, its treatment for shingles, but the results of a study on its losmapimod drug for heart treatment were disappointing. The pharmaceuticals giant said its LABA safety stud

GSK heart drug disappoints in study, shingles vaccine on track

LONDON, Oct 27 (Reuters) - An experimental heart drug from GlaxoSmithKline called losmapimod failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its pipeline of new medicines. However, a new shingles vaccine succeeded in a seco

GlaxoSmithKline Gets Good Results On Asthma And Shingles Treatments

Novartis Q3 income misses forecast as Alcon, dollar hit results

ZURICH, Oct 27 (Reuters) - Novartis reported third-quarter core net income fell, missing analyst forecasts as the cancer portfolio acquired from GlaxoSmithKline and the Swiss company's newer products failed to offset continuing weakness at its eye-care business Alcon. The stronger dollar al

PRESS: Woodford Calling For GlaxoSmithKline Break-Up - Sky News

UPDATE 2-World's first malaria vaccine delayed as WHO experts urge caution

* GSK shot likely to cost $5/dose, won't stamp out malaria * Pilot tests in children expected to take 3-5 years * Experts don't recommend use of vaccine in young babies (Adds detail on cost; comment from GSK, MSF, outside expert) By Tom Miles and Ben Hirschler GENEVA/LON

GlaxoSmithKline's Volibris drug receives positive recommendation

(ShareCast News) - A committee of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's Volibris drug be approved for use in combination treatment for patients with pulmonary arterial hypertension. The Committee for Medicinal Products for Human Use (CHMP) announced the formal recomme